机构：[1]Hongqiao International Institute of Medicine, Tongren Hospital and State Key Laboratory of Systems Medicine for Cancer, Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China[2]Department of General Surgery, Tongren Hospital, SJTU-SM, Shanghai, 200336, China[3]Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Biomedical Research, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China[4]Key Laboratory of Basic Pharmacology of Ministry of Education & Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, 563003, China
Chemoimmunotherapy is an emerging paradigm in the clinic for treating several malignant diseases, such as nonsmall cell lung cancer, breast cancer, and large B-cell lymphoma. However, the efficacy of this strategy is still restricted by serious adverse events and a high therapeutic termination rate, presumably due to the lack of tumor-targeted distribution of both chemotherapeutic and immunotherapeutic agents. Targeted drug delivery has the potential to address this issue. Among the most promising nanocarriers in clinical translation, liposomes have drawn great attention in cancer chemoimmunotherapy in recent years. Liposomes-enabled cancer chemoimmunotherapy has made significant progress in clinics, with impressive therapeutic outcomes. This review summarizes the latest preclinical and clinical progress in liposome-enabled cancer chemoimmunotherapy and discusses the challenges and future directions of this field.
基金：
China Postdoctoral Science Foundation [2022XD035]; [2022TQ0213]; [2022M722139]; [2023M742364]
第一作者机构：[1]Hongqiao International Institute of Medicine, Tongren Hospital and State Key Laboratory of Systems Medicine for Cancer, Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
通讯作者：
通讯机构：[1]Hongqiao International Institute of Medicine, Tongren Hospital and State Key Laboratory of Systems Medicine for Cancer, Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China[4]Key Laboratory of Basic Pharmacology of Ministry of Education & Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, 563003, China[*1]Hongqiao International Institute of Medicine, Tongren Hospital and State Key Laboratory of Systems Medicine for Cancer, Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
推荐引用方式(GB/T 7714)：
Zhang Lele,Shi Jiangpei,Zhu Mao-Hua,et al.Liposomes-enabled cancer chemoimmunotherapy[J].BIOMATERIALS.2025,313:doi:10.1016/j.biomaterials.2024.122801.
APA：
Zhang, Lele,Shi, Jiangpei,Zhu, Mao-Hua,Huang, Yanhu,Lu, Qin...&Fang, Chao.(2025).Liposomes-enabled cancer chemoimmunotherapy.BIOMATERIALS,313,
MLA：
Zhang, Lele,et al."Liposomes-enabled cancer chemoimmunotherapy".BIOMATERIALS 313.(2025)
医学